Case report: dose adjustment of warfarin using genetic information and plasma concentration monitoring

20142 citationsJournal Article

Authors

Tohru Aomori · Gunma University

Yukiyoshi Fujita · Gunma Prefectural Cardiovascular Center

K. Obayashi · Gunma University Hospital

Hajime Satō · Sapporo Medical University

Kazuma Kiyotani · University of Chicago Medical Center

Katsunori Nakamura · Gunma University Hospital

Tomonori Nakamura

Abstract

The patient required a high warfarin dose because of the VKORC1 genotype, and induction of CYP2C9 by carbamazepine. We improved the patient's pharmacotherapy based on her genetic information.

Topics & Keywords

Pharmacogenetics and Drug Metabolism Eicosanoids and Hypertension Pharmacology Hormonal Regulation and Hypertension

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Pharmacy and Therapeutics

Volume 39, Issue 3, pp. 319-321

DOI: 10.1111/jcpt.12135

Field-Weighted Citation Impact: 0.00